Table 1 Baseline characteristics and demographics of the patients and controls enrolled in Stage 1 and Stage 2.

From: A novel type 2 diabetes risk allele increases the promoter activity of the muscle-specific small ankyrin 1 gene

 

Stage 1

Stage 2

Cases

Controls

P

Cases

Controls

P

Number

441

441

 

733

733

 

Male, n (%)

225 (51.0%)

238 (54%)

NS

441 (60.2%)

454 (61.9%)

NS

Age, yr

59.3 ± 11.1

59.3 ± 11.2

NS

57.1 ± 13.1

56.9 ± 13.1

NS

Smoking, n (%)

74 (16.9%)

–

–

138 (19.1%)

–

–

Diabetes duration, yr

8.32 ± 6.91

–

–

7.74 ± 6.82

–

–

HbA1c, %

9.05 ± 2.51

–

–

9.13 ± 2.54

–

–

FPG, mM

7.86 ± 3.22

5.05 ± 0.47

<0.001

7.91 ± 3.18

5.06 ± 0.50

<0.001

BMI, kg/m2

24.7 ± 3.75

23.6 ± 3.37

<0.001

24.9 ± 3.93

23.7 ± 3.24

<0.001

Triglycerides, mM

1.87 ± 2.01

1.49 ± 0.96

0.002

2.04 ± 2.38

1.58 ± 1.02

<0.001

HDL cholesterol, mM

1.07 ± 0.30

1.41 ± 0.35

<0.001

1.10 ± 0.31

1.38 ± 0.34

<0.001

LDL cholesterol, mM

2.90 ± 1.58

2.81 ± 0.68

NS

2.94 ± 1.37

2.83 ± 0.67

NS

Systolic BP, mm Hg

143 ± 22.4

124 ± 16.6

<0.001

141 ± 22.9

126 ± 17.7

<0.001

Diastolic BP, mm Hg

80.6 ± 11.3

75 ± 10.5

<0.001

80.9 ± 11.7

76 ± 11.1

<0.001

  1. Data are expressed as the number (%) or average ± SD. Abbreviations used: HbA1c, haemoglobinA1c; FPG, Fasting Plasma Glucose; BMI, body mass index; BP, blood pressure; NS, no significant difference compared between cases and controls.
Back to article page